valproic acid has been researched along with Neurofibromatosis 2 in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Neurofibromatosis 2: An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we show that VPA up-regulates the neurofibromatosis type 2 (NF2) tumor suppressor, merlin, to regulate neurite outgrowth through the interaction with paxillin." | 5.35 | Neurofibromatosis 2 tumor suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin. ( Kiyokawa, N; Kusakawa, S; Miyamoto, Y; Mizutani, R; Nakajima, H; Sanbe, A; Tanoue, A; Torii, T; Yamauchi, J, 2008) |
| "Here, we show that VPA up-regulates the neurofibromatosis type 2 (NF2) tumor suppressor, merlin, to regulate neurite outgrowth through the interaction with paxillin." | 1.35 | Neurofibromatosis 2 tumor suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin. ( Kiyokawa, N; Kusakawa, S; Miyamoto, Y; Mizutani, R; Nakajima, H; Sanbe, A; Tanoue, A; Torii, T; Yamauchi, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Subbiah, V | 1 |
| Slopis, J | 1 |
| Hong, DS | 1 |
| Ketonen, LM | 1 |
| Hamilton, J | 1 |
| McCutcheon, IE | 1 |
| Kurzrock, R | 1 |
| Yamauchi, J | 1 |
| Miyamoto, Y | 1 |
| Kusakawa, S | 1 |
| Torii, T | 1 |
| Mizutani, R | 1 |
| Sanbe, A | 1 |
| Nakajima, H | 1 |
| Kiyokawa, N | 1 |
| Tanoue, A | 1 |
1 trial available for valproic acid and Neurofibromatosis 2
| Article | Year |
|---|---|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents | 2012 |
1 other study available for valproic acid and Neurofibromatosis 2
| Article | Year |
|---|---|
Neurofibromatosis 2 tumor suppressor, the gene induced by valproic acid, mediates neurite outgrowth through interaction with paxillin.
Topics: Animals; Anticonvulsants; Carrier Proteins; Cell Line; Genes, Neurofibromatosis 2; Genes, Tumor Supp | 2008 |